Monitoring disease response to tyrosine kinase inhibitor therapy in CML
Published 2009 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Monitoring disease response to tyrosine kinase inhibitor therapy in CML
Authors
Keywords
-
Journal
Hematology-American Society of Hematology Education Program
Volume 2009, Issue 1, Pages 477-487
Publisher
American Society of Hematology
Online
2009-12-12
DOI
10.1182/asheducation-2009.1.477
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment of Philadelphia-Positive Chronic Myeloid Leukemia with Imatinib: Importance of a Stable Molecular Response
- (2009) F. Palandri et al. CLINICAL CANCER RESEARCH
- Impact of BaselineBCR-ABLMutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
- (2009) Timothy Hughes et al. JOURNAL OF CLINICAL ONCOLOGY
- Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value
- (2009) A Hochhaus et al. LEUKEMIA
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
- (2009) A Hochhaus et al. LEUKEMIA
- Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
- (2008) T. P. Hughes et al. BLOOD
- Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
- (2008) C. S. Tam et al. BLOOD
- Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
- (2008) E. Jabbour et al. BLOOD
- European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
- (2008) D. Marin et al. BLOOD
- Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
- (2008) R. A. Larson et al. BLOOD
- Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
- (2008) S. Branford et al. BLOOD
- ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
- (2008) T. Ernst et al. HAEMATOLOGICA
- Monitoring treatment of chronic myeloid leukemia
- (2008) M. Baccarani et al. HAEMATOLOGICA
- Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
- (2008) Sara Redaelli et al. JOURNAL OF CLINICAL ONCOLOGY
- An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Chronic Myeloid Leukemia Patients Undergoing Kinase Inhibitor Therapy
- (2008) Jennifer Laudadio et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels
- (2008) Donna L. Forrest et al. LEUKEMIA RESEARCH
- BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations
- (2008) T.-S. Lee et al. MOLECULAR CANCER THERAPEUTICS
- Long-Term Outcome of Complete Cytogenetic Responders After Imatinib 400 mg in Late Chronic Phase, Philadelphia-Positive Chronic Myeloid Leukemia: The GIMEMA Working Party on CML
- (2007) Francesca Palandri et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More